Mar 31, 2023

Entrada Therapeutics Q1 2023 Earnings Report

Total Revenue
$25.3M
EPS
-$0.21
Previous year: -$0.69
-69.6%
R&D Expenses
$23.1M
G&A Expenses
$7.94M
Gross Profit
$24.7M
Cash and Equivalents
$228M
Previous year: $84.6M
+169.0%
Free Cash Flow
$202M
Previous year: -$21.6M
-1034.6%
Total Assets
$476M
Previous year: $317M
+50.2%

Entrada Therapeutics

Entrada Therapeutics

Entrada Therapeutics Revenue by Segment